Volume 10, Number 5—May 2004
Research
Clinical Manifestations, Laboratory Findings, and Treatment Outcomes of SARS Patients
Jann-Tay Wang*, Wang-Huei Sheng*, Chi-Tai Fang*, Yee-Chun Chen*, Jiun-Ling Wang*, Chong-Jen Yu*, Shan-Chwen Chang*
, and Pan-Chyr Yang*
, and Pan-Chyr Yang*
Table 4
Complications found in 76 SARS patientsa
| Complication | No. of patients (%) |
|---|---|
| Rhabdomyolysis |
4 (5.3) |
| Peripheral neuropathy |
5 (6.6) |
| Acute renal failure |
3 (3.9) |
| Gastrointestinal bleeding |
2 (2.6) |
| Acute myocardial infarction |
1 (1.3) |
| Bacteria superinfection |
10 (13.2) |
| Candida parapsilosis superinfection |
1 (1.3) |
| MRSA |
4 (5.3) |
| MRSE |
2 (2.6) |
| Enterococci |
3 (3.9) |
| Acinetobacter baumannii |
3 (3.9) |
| Klebsiella pneumoniae |
2 (2.6) |
| Enterobacter cloacae |
1 (1.3) |
| Serratia marcescense |
1 (1.3) |
| Total | 18 (23.7) |
aSARS, severe acute respiratory syndrome; MRSA, methicillin-resistant Staphylococcus aureus; MRSE, methicillin-resistant Staphylococcus epidermidis. Some patients experience more than one complication.
Page created: February 22, 2011
Page updated: February 22, 2011
Page reviewed: February 22, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.